Frederick A. Ofosu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Frederick A. Ofosu has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
Lori Dewar
Department of Pathology and Molecular Medicine, McMaster University, and Canadian Blood Services, Hamilton, Ontario L8N 3Z5, Canada
8 shared publicationsJ. Hirsh
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
7 shared publicationsM.A. Blajchman
Canadian Red Cross Blood Transfusion Service and Department of Pathology, McMaster University, Hamilton
7 shared publicationsMichael R. Buchanan
McMaster University, Dept of Surgery, Hamilton, Ontario, Canada
7 shared publicationsJohn Freedman
6 shared publicationsJohn W. Fenton
6 shared publications
Latest Publications
- 1 December 2015
- Published by Elsevier in Thrombosis Research
- Vol. 136 (6) , 1053-1054
An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes
- 1 December 2015
- Published by Elsevier in Thrombosis Research
- Vol. 136 (6) , 1053-1054
An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes
- 1 May 2014
- Published by Elsevier in Thrombosis Research
- Vol. 133 (5) , 697-8
Appropriate assessment of the functional consequences of platelet cyclooxygenase-1 inhibition by aspirin in vivo.
- 1 May 2014
- Published by Elsevier in Thrombosis Research
- Vol. 133 (5) , 697-8
Appropriate assessment of the functional consequences of platelet cyclooxygenase-1 inhibition by aspirin in vivo.
- 1 July 2013
- Published by Elsevier in Thrombosis Research
- Vol. 132 (1) , 1-2
Effective, selective and specific inhibition of COX-1 may overcome the "aspirin paradox".
- 1 July 2013
- Published by Elsevier in Thrombosis Research
- Vol. 132 (1) , 1-2
Effective, selective and specific inhibition of COX-1 may overcome the "aspirin paradox".
- 4 June 2012
- Published by Wiley in Haemophilia
- Vol. 18 (6) , 917-925
The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studiesin vitro
A fraction of FVIII:Ag in commercial recombinant FVIII (rFVIII) cannot bind VWF whereas all the FVIII:Ag in plasma-derived FVIII (pd-FVIII) concentrates does. To compare the FVIII:C activities of the fractions of rFVIII:Ag that can and cannot bind VWF. The FVIII:Ag contents of the rFVIII Kogenate, and Advate and a pd-FVIII-pd-VWF (Fanhdi) were measured by ELISA. The FX activation was initiated by adding 1.0 IU of FVIII:C of each FVIII-containing product to a coagulant phospholipids suspension containing 1.0 nm FIXa, 100 nm FX, 1 μm hirudin and 2 mm calcium chloride and measured after 1, 5 and 10 min. The same approach was followed after adding 2.0 IU of pd-VWF to1.0 IU of FVIII:C of Kogenate or Advate. The FVIII:Ag content/IU of FVIII:C of Kogenate, Advate and Fanhdi were 1.80 ± 0.05, 1.31 ± 0.9 and 0.84 ± 1.5 IU respectively. Only Kogenate and Advate effectively enhanced FX activation 1 min after adding each FVIII:C to the coagulant suspension containing FIXa and FX. Thus, the FXa initially generated by FIXa readily activated FVIII:C in control Kogenate and Advate to thereby effectively enhance FX activation while the VWF in Fanhdi continued to suppress FX activation for up to 10 min. Addition of pd-VWF to Kogenate or Advate effectively decreased their enhancements of FX activation to the same level as Fanhdi over 10 min. The FVIII:Ag fraction in Kogenate and Advate that cannot bind VWF appears to be inactive as it has no measureable FVIII:C activity in the presence of added VWF in vitro.
- 4 June 2012
- Published by Wiley in Haemophilia
- Vol. 18 (6) , 917-925
The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studiesin vitro
A fraction of FVIII:Ag in commercial recombinant FVIII (rFVIII) cannot bind VWF whereas all the FVIII:Ag in plasma-derived FVIII (pd-FVIII) concentrates does. To compare the FVIII:C activities of the fractions of rFVIII:Ag that can and cannot bind VWF. The FVIII:Ag contents of the rFVIII Kogenate, and Advate and a pd-FVIII-pd-VWF (Fanhdi) were measured by ELISA. The FX activation was initiated by adding 1.0 IU of FVIII:C of each FVIII-containing product to a coagulant phospholipids suspension containing 1.0 nm FIXa, 100 nm FX, 1 μm hirudin and 2 mm calcium chloride and measured after 1, 5 and 10 min. The same approach was followed after adding 2.0 IU of pd-VWF to1.0 IU of FVIII:C of Kogenate or Advate. The FVIII:Ag content/IU of FVIII:C of Kogenate, Advate and Fanhdi were 1.80 ± 0.05, 1.31 ± 0.9 and 0.84 ± 1.5 IU respectively. Only Kogenate and Advate effectively enhanced FX activation 1 min after adding each FVIII:C to the coagulant suspension containing FIXa and FX. Thus, the FXa initially generated by FIXa readily activated FVIII:C in control Kogenate and Advate to thereby effectively enhance FX activation while the VWF in Fanhdi continued to suppress FX activation for up to 10 min. Addition of pd-VWF to Kogenate or Advate effectively decreased their enhancements of FX activation to the same level as Fanhdi over 10 min. The FVIII:Ag fraction in Kogenate and Advate that cannot bind VWF appears to be inactive as it has no measureable FVIII:C activity in the presence of added VWF in vitro.
- 24 April 2012
- Published by Wiley in Haemophilia
- Vol. 18 (s2) , 8-14
Management of bleeding disorders: basic science
Summary. Development of factor VIII (FVIII) inhibitors is the most severe and challenging complication of haemophilia A treatment and represents the highest economic burden for a chronic disease. Therefore, major research efforts are ongoing to optimize the therapeutic approaches able to minimize this complication. FVIII inhibitors have variable immuno‐reactivity against different FVIII concentrates and generally have a lower reactivity against von Willebrand factor (VWF)‐containing FVIII concentrates than plasma‐derived FVIII (pdFVIII) or recombinant FVIII (rFVIII) that are devoid of VWF, in particular when the inhibitors are directed against the light chain of FVIII. This paper provides an overview of several in vitro and in vivo studies that compared three clinically available clinical FVIII products (Kogenate®, Bayer AG, Leverkusen, Germany; Advate®, Baxter Healthcare, Zurich, Switzerland; and Fanhdi®, Grifols S.A., Barcelona, Spain) in order to evaluate the functional actvity of the FVIII fractions in rFVIII that cannot bind VWF; explore the use of the thrombin generation assay (TGA) as a potential tool for optimizing the choice of FVIII concentrate for use in haemophilia A patients with inhibitors; compare the kinetics of the interactions between anti‐FVIII antibodies and FVIII both in the presence/absence of VWF, using surface plasmon resonance.
- 24 April 2012
- Published by Wiley in Haemophilia
- Vol. 18 (s2) , 8-14
Management of bleeding disorders: basic science
Summary. Development of factor VIII (FVIII) inhibitors is the most severe and challenging complication of haemophilia A treatment and represents the highest economic burden for a chronic disease. Therefore, major research efforts are ongoing to optimize the therapeutic approaches able to minimize this complication. FVIII inhibitors have variable immuno‐reactivity against different FVIII concentrates and generally have a lower reactivity against von Willebrand factor (VWF)‐containing FVIII concentrates than plasma‐derived FVIII (pdFVIII) or recombinant FVIII (rFVIII) that are devoid of VWF, in particular when the inhibitors are directed against the light chain of FVIII. This paper provides an overview of several in vitro and in vivo studies that compared three clinically available clinical FVIII products (Kogenate®, Bayer AG, Leverkusen, Germany; Advate®, Baxter Healthcare, Zurich, Switzerland; and Fanhdi®, Grifols S.A., Barcelona, Spain) in order to evaluate the functional actvity of the FVIII fractions in rFVIII that cannot bind VWF; explore the use of the thrombin generation assay (TGA) as a potential tool for optimizing the choice of FVIII concentrate for use in haemophilia A patients with inhibitors; compare the kinetics of the interactions between anti‐FVIII antibodies and FVIII both in the presence/absence of VWF, using surface plasmon resonance.
- 1 January 2012
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 107 (02) , 201-214
A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins
Summary: With the expiry or pending expiry of originator low-molecular-weight heparin (LMWH) patents, pharmaceutical companies have invested in developing non-proprietary versions of LMWHs. LMWHs are manufactured by depolymerising highly purified unfractionated heparin. In contrast to traditional synthetic drugs with well-defined chemical structures, LMWHs contain complex oligosaccharide mixtures and the different manufacturing processes for LMWHs add to the heterogeneity in their physicochemical properties such that the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) consider existing originator LMWHs to be distinct medicinal entities that are not clinically interchangeable. The FDA views LMWHs as drugs and has approved two non-proprietary (generic) LMWHs, using the Abbreviated New Drug Application pathway. In contrast, the World Health Organization and the EMA view LMWHs as biological medicines. Therefore, the EMA and also the Scientific and Standardization Subcommittee on Anticoagulation of the International Society on Thrombosis and Haemostasis and the South Asian Society of Atherosclerosis and Thrombosis have all published specific guidelines for assessing non-proprietary (biosimilar) LMWHs. This manuscript reviews why there are two distinct pathways for approving non-proprietary LMWHs. Available literature on non-proprietary LMWHs approved in some jurisdictions is also reviewed in order to assess whether they satisfy the requirements for LMWHs in the three guidance documents. The review also highlights some of the significant difficulties the two pathways pose for manufacturers and an urgent need to develop a consensus governing the manufacture and regulation of non-proprietary LMWHs to make them more widely available.
- 1 January 2012
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 107 (02) , 201-214
A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins
Summary: With the expiry or pending expiry of originator low-molecular-weight heparin (LMWH) patents, pharmaceutical companies have invested in developing non-proprietary versions of LMWHs. LMWHs are manufactured by depolymerising highly purified unfractionated heparin. In contrast to traditional synthetic drugs with well-defined chemical structures, LMWHs contain complex oligosaccharide mixtures and the different manufacturing processes for LMWHs add to the heterogeneity in their physicochemical properties such that the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) consider existing originator LMWHs to be distinct medicinal entities that are not clinically interchangeable. The FDA views LMWHs as drugs and has approved two non-proprietary (generic) LMWHs, using the Abbreviated New Drug Application pathway. In contrast, the World Health Organization and the EMA view LMWHs as biological medicines. Therefore, the EMA and also the Scientific and Standardization Subcommittee on Anticoagulation of the International Society on Thrombosis and Haemostasis and the South Asian Society of Atherosclerosis and Thrombosis have all published specific guidelines for assessing non-proprietary (biosimilar) LMWHs. This manuscript reviews why there are two distinct pathways for approving non-proprietary LMWHs. Available literature on non-proprietary LMWHs approved in some jurisdictions is also reviewed in order to assess whether they satisfy the requirements for LMWHs in the three guidance documents. The review also highlights some of the significant difficulties the two pathways pose for manufacturers and an urgent need to develop a consensus governing the manufacture and regulation of non-proprietary LMWHs to make them more widely available.
- Open Access
- 15 December 2010
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 17 (1) , 5-8
The United States Food and Drugs Administration Approves a Generic Enoxaparin
The Food and Drug Administration (FDA) approved on July 23, 2010, the abbreviated new drug application (ANDA) by Sandoz Inc for a generic enoxaparin (Lovenox) as the FDA is satisfied with the active ingredient ‘‘sameness’’ and the interchangeability of Lovenox with this generic version. Regulatory authorities that consider low-molecular-weight heparins (LMWHs) as drugs approve generic LMWHs via an ANDA pathway, whereas EMEA views them as biological medicines and will therefore regulate copies of LMWHs via a biosimilar pathway because only similar copies can be manufactured. Furthermore, European Medicines Agency (EMEA) requires appropriately powered clinical trails to establish comparable efficacy and safety profiles for biosimilar and their branded LMWHs counterparts. The safety issues that have led to withdrawal of some generic LMWHs from some Asian and South American countries mandate the need for a broad consensus defining the minimum attributes copies of LMWHs required for efficacy and safety.
- 15 December 2010
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 17 (1) , 5-8
Open AccessThe United States Food and Drugs Administration Approves a Generic Enoxaparin
The Food and Drug Administration (FDA) approved on July 23, 2010, the abbreviated new drug application (ANDA) by Sandoz Inc for a generic enoxaparin (Lovenox) as the FDA is satisfied with the active ingredient ‘‘sameness’’ and the interchangeability of Lovenox with this generic version. Regulatory authorities that consider low-molecular-weight heparins (LMWHs) as drugs approve generic LMWHs via an ANDA pathway, whereas EMEA views them as biological medicines and will therefore regulate copies of LMWHs via a biosimilar pathway because only similar copies can be manufactured. Furthermore, European Medicines Agency (EMEA) requires appropriately powered clinical trails to establish comparable efficacy and safety profiles for biosimilar and their branded LMWHs counterparts. The safety issues that have led to withdrawal of some generic LMWHs from some Asian and South American countries mandate the need for a broad consensus defining the minimum attributes copies of LMWHs required for efficacy and safety.
- 1 July 2009
- Published by Elsevier in Thrombosis Research
- Vol. 124 (3) , 281-287
Hypercoagulability after trauma: Hemostatic changes and relationship to venous thromboembolism
- 1 July 2009
- Published by Elsevier in Thrombosis Research
- Vol. 124 (3) , 281-287
Hypercoagulability after trauma: Hemostatic changes and relationship to venous thromboembolism
- 1 April 2009
- Published by Elsevier in Clinical Therapeutics
- Vol. 31 (4) , 679-691
A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins
- 1 April 2009
- Published by Elsevier in Clinical Therapeutics
- Vol. 31 (4) , 679-691
A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins
- 30 January 2009
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 48 (7) , 1562-1572
Early Intraplatelet Signaling Enhances the Release of Human Platelet PAR-1 and -4 Amino-Terminal Peptides in Response to Thrombin
Activation of washed human platelets initiated with α-thrombin, SFLLRN, or AYPGKF invariably results in the generation of PAR-1-(1−41) and PAR-4-(1−47). PAR-1-(1−41) and PAR-4-(1−47) are amino-terminal peptides generated when PAR-1 and -4 are cleaved in their first extracellular domains after R41 and R47, respectively, to expose the tethered ligand domains of PAR-1 and -4. Since soybean trypsin inhibitor decreases generation of PAR-1-(1−41) and PAR-4-(1−47) and other platelet aggregation-related responses to these three agonists, but does not inactivate α-thrombin, a platelet trypsin-like proteinase apparently activates PAR-1 and -4 to propagate PAR-dependent platelet responses. This study identified the signaling pathways implicated in the generation of the platelet proteinase that in turn produces PAR-1-(1−41) and PAR-4-(1−47), to thereby drive the subsequent PAR-dependent platelet aggregation-related responses to α-thrombin, SFLLRN, or AYPGKF. Only inhibitors of signaling enzymes that prevented ATP release (forskolin, PGE1, or BIMI-1) prevented or delayed the generation of PAR-1-(1−41) and PAR-4-(1−47) in response to all three agonists. SBTI prevented platelet aggregation initiated by α-thrombin, SFLLRN, or AYPGKF but did so less effectively when it was added 10 s after each agonist. Thus, the platelet-derived proteinase acts within 10 s of each agonist addition to generate PAR-1-(1−41) and PAR-4-(1−47). Furthermore, α-thrombin may not effectively catalyze PAR-1-(1−41) and PAR-4-(1−47) generation. We propose that unidentified ATP-dependent phosphorylation reactions catalyzed by PKC help to generate the platelet-derived proteinase that propagates human platelet PAR-1 and -4 activation by the three agonists.
- 30 January 2009
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 48 (7) , 1562-1572
Early Intraplatelet Signaling Enhances the Release of Human Platelet PAR-1 and -4 Amino-Terminal Peptides in Response to Thrombin
Activation of washed human platelets initiated with α-thrombin, SFLLRN, or AYPGKF invariably results in the generation of PAR-1-(1−41) and PAR-4-(1−47). PAR-1-(1−41) and PAR-4-(1−47) are amino-terminal peptides generated when PAR-1 and -4 are cleaved in their first extracellular domains after R41 and R47, respectively, to expose the tethered ligand domains of PAR-1 and -4. Since soybean trypsin inhibitor decreases generation of PAR-1-(1−41) and PAR-4-(1−47) and other platelet aggregation-related responses to these three agonists, but does not inactivate α-thrombin, a platelet trypsin-like proteinase apparently activates PAR-1 and -4 to propagate PAR-dependent platelet responses. This study identified the signaling pathways implicated in the generation of the platelet proteinase that in turn produces PAR-1-(1−41) and PAR-4-(1−47), to thereby drive the subsequent PAR-dependent platelet aggregation-related responses to α-thrombin, SFLLRN, or AYPGKF. Only inhibitors of signaling enzymes that prevented ATP release (forskolin, PGE1, or BIMI-1) prevented or delayed the generation of PAR-1-(1−41) and PAR-4-(1−47) in response to all three agonists. SBTI prevented platelet aggregation initiated by α-thrombin, SFLLRN, or AYPGKF but did so less effectively when it was added 10 s after each agonist. Thus, the platelet-derived proteinase acts within 10 s of each agonist addition to generate PAR-1-(1−41) and PAR-4-(1−47). Furthermore, α-thrombin may not effectively catalyze PAR-1-(1−41) and PAR-4-(1−47) generation. We propose that unidentified ATP-dependent phosphorylation reactions catalyzed by PKC help to generate the platelet-derived proteinase that propagates human platelet PAR-1 and -4 activation by the three agonists.